Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits.
This paper compares the pharmacological properties of a new succinyl dermatan sulphate derivative (Suc-DS) to those of the natural dermatan sulphate (DS). Suc-DS was on average 2-3 times more potent than DS in catalysing the inhibition of thrombin by heparin cofactor II and in prolonging the activated partial thromboplastin time and the thrombin clotting time. After bolus injection, Suc-DS was also 2-3 times more potent than DS to prevent experimental venous thrombosis in a Wessler model. Thromboplastin or human serum were used as the thrombogenic stimulus. In contrast, the bleeding effect assessed by rat tail transection technique was comparable. After bolus intravenous injection, the pharmacodynamics of Suc-DS indicated a lower volume of distribution, which was close to the plasma volume, and a slightly lower clearance of elimination. Therefore this chemical alteration of natural DS yields a new compound with an improved antithrombotic benefit/haemorrhagic risk ratio.
Saivin
S
S
Unité de Pharmacocinétique, Hôpital Purpan, Toulouse, France.
Caranobe
C
C
Petitou
M
M
Sie
P
P
Lormeau
J C
JC
Level
M
M
Crepon
B
B
Houin
G
G
Boneu
B
B
D000818:Animals; D001760:Bleeding Time; D001777:Blood Coagulation / Q000187:drug effects*; D003871:Dermatan Sulfate / Q000097:blood / Q000627:therapeutic use* / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D011817:Rabbits; D051381:Rats; D013386:Succinates / Q000097:blood / Q000627:therapeutic use*; D013924:Thrombophlebitis / Q000517:prevention & control*
D013386:Succinates; C074584:succinyl dermatan sulfate; D003871:Dermatan Sulfate